288 related articles for article (PubMed ID: 25595221)
21. OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE.
Agarwal P; Barbano R; Moore H; Schwartz M; Zuzek A; Sadeghi M; Patel A
Front Neurol; 2022; 13():914486. PubMed ID: 35847221
[TBL] [Abstract][Full Text] [Related]
22. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
Figgitt DP; Noble S
Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
[TBL] [Abstract][Full Text] [Related]
23. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
24. Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study.
Kongsaengdao S; Arayawithchanont A; Samintharapanya K; Rojanapitayakorn P; Maneeton B; Maneeton N
Toxins (Basel); 2021 Oct; 13(10):. PubMed ID: 34678987
[TBL] [Abstract][Full Text] [Related]
25. Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes.
Jinnah HA; Goodmann E; Rosen AR; Evatt M; Freeman A; Factor S
J Neurol; 2016 Jun; 263(6):1188-94. PubMed ID: 27113604
[TBL] [Abstract][Full Text] [Related]
26. Improvement in Quality of Life with OnabotulinumtoxinA for Cervical Dystonia: POSTURe.
Petitclerc M; Cloutier M; Naud P; Langlois M; Bhogal M; Davidovic G
Can J Neurol Sci; 2021 Sep; 48(5):676-684. PubMed ID: 33342445
[TBL] [Abstract][Full Text] [Related]
27. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
28. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
[TBL] [Abstract][Full Text] [Related]
29. Botulinum Toxin Treatment of Cervical Dystonia.
Bledsoe IO; Comella CL
Semin Neurol; 2016 Feb; 36(1):47-53. PubMed ID: 26866496
[TBL] [Abstract][Full Text] [Related]
30. Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale.
Espay AJ; Trosch R; Suarez G; Johnson J; Marchese D; Comella C
Parkinsonism Relat Disord; 2018 Jul; 52():94-97. PubMed ID: 29530726
[TBL] [Abstract][Full Text] [Related]
31. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.
Matharu M; Pascual J; Nilsson Remahl I; Straube A; Lum A; Davar G; Odom D; Bennett L; Proctor C; Gutierrez L; Andrews E; Johannes C
Cephalalgia; 2017 Dec; 37(14):1384-1397. PubMed ID: 28758415
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia.
Naumann M; Yakovleff A; Durif F;
J Neurol; 2002 Jan; 249(1):57-63. PubMed ID: 11954869
[TBL] [Abstract][Full Text] [Related]
33. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
Dressler D; Kupsch A; Seitzinger A; Paus S
Eur J Neurol; 2014 Mar; 21(3):459-62. PubMed ID: 24433495
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
[TBL] [Abstract][Full Text] [Related]
35. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.
Samotus O; Lee J; Jog M
J Neurol; 2018 Jun; 265(6):1269-1278. PubMed ID: 29557988
[TBL] [Abstract][Full Text] [Related]
36. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.
Han Y; Stevens AL; Dashtipour K; Hauser RA; Mari Z
J Neurol; 2016 Apr; 263(4):772-80. PubMed ID: 26914922
[TBL] [Abstract][Full Text] [Related]
37. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting.
Dowson AJ; Kilminster SG; Salt R
Drugs R D; 2008; 9(3):147-58. PubMed ID: 18457467
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.
Comella CL; Jankovic J; Hauser RA; Patel AT; Banach MD; Ehler E; Vitarella D; Rubio RG; Gross TM;
Neurology; 2024 Feb; 102(4):e208091. PubMed ID: 38295339
[TBL] [Abstract][Full Text] [Related]
39. Botulinum Toxin Effects on Sensorimotor Integration in Focal Dystonias.
De Bartolo MI; Manzo N; Ferrazzano G; Baione V; Belvisi D; Fabbrini G; Berardelli A; Conte A
Toxins (Basel); 2020 Apr; 12(5):. PubMed ID: 32344856
[TBL] [Abstract][Full Text] [Related]
40. Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study.
Patel AT; Lew MF; Dashtipour K; Isaacson S; Hauser RA; Ondo W; Maisonobe P; Wietek S; Rubin B; Brashear A
PLoS One; 2021; 16(2):e0245827. PubMed ID: 33524060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
